References
- Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med. 2019;25(9):1341-55. https://doi.org/10.1038/s41591-019-0564-6 PMid:31501612
- Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat Rev Clin Oncol. 2021;18(11):715-27. https://doi.org/10.1038/s41571-021-00530-z PMid:34230645
- Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15(1):31-46. https://doi.org/10.1038/nrclinonc.2017.128 PMid:28857075
- Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024-8. https://doi.org/10.1073/pnas.86.24.10024 PMid:2513569
- Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol. 2002;20(1):70-5. https://doi.org/10.1038/nbt0102-70 PMid:11753365
- Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 2021;28(9):513-27. https://doi.org/10.1038/s41434-021-00246-w PMid:33753909
- Deming D, Wang K, Wei C, Feng D, Liu Y, He Q, et al. The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma. Front Immunol. 2021;12:609421. https://doi.org/10.3389/fimmu.2021.609421 PMid:33767695
- Tian Y, Li Y, Shao Y, Zhang Y. Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol. 2020;13(1):54. https://doi.org/10.1186/s13045-020-00890-6 PMid:32423475
- Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18(2):71-84. https://doi.org/10.1038/s41571-020-0427-6 PMid:32978608
- Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-48. https://doi.org/10.1056/NEJMoa1709866 PMid:29385370
- Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42. https://doi.org/10.1016/S1470-2045(18)30864-7 PMid:30518502
- Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet. 2020;396(10254):839-52. https://doi.org/10.1016/S0140-6736(20)31366-0 PMid:32888407
- Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331-42. https://doi.org/10.1056/NEJMoa1914347 PMid:32242358
- Feigal EG, Cosenza ME. Cellular-based therapies. In: Translational Medicine. United States: CRC Press; 2021. p. 359-80.
- Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-16. https://doi.org/10.1056/NEJMoa2024850 PMid:33626253
- Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-Year follow-up. J Clin Oncol. 2023;41(6):1265-74. https://doi.org/10.1200/JCO.22.00842 PMid:35658469
- Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial. Nat Med. 2022;28(2):325-32. https://doi.org/10.1038/s41591-021-01622-0 PMid:34921238
- Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: What we know so far. Nat Rev Clin Oncol. 2023;20:359-71. https://doi.org/10.1038/s41571-023-00754-1 PMid:37055515
- Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91-103. https://doi.org/10.1016/S1470-2045(21)00591-X PMid:34895487
- Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory difuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8. https://doi.org/10.1182/blood-2017-03-769620 PMid:28774879
- Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502. https://doi.org/10.1016/S0140-6736(21)01222-8 PMid:34097852
- Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45-55. https://doi.org/10.1016/j.blre.2018.11.002 PMid:30528964
- Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, et al. Preparing for CAR T cell therapy: Patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19(5):342-55. https://doi.org/10.1038/s41571-022-00607-3 PMid:35318469
- Yip A, Webster RM. The market for chimeric antigen receptor T cell therapies. Nat Rev Drug Discov. 2018;17(3):161-2. https://doi.org/10.1038/nrd.2017.266 PMid:29375140
- Albelda SM. CAR T cell therapy for patients with solid tumours: Key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21:47-66. https://doi.org/10.1038/s41571-023-00832-4 PMid:37904019
- Abou-el-Enein M, Elsallab M, Feldman SA, Andrew D. Fesnak AD, Heslop HE, et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2021;2(5):408-22. https://doi.org/10.1158/2643-3230.BCD-21-0084 PMid:34568831
- Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol. 2019;37(24):2105-19. https://doi.org/10.1200/JCO.18.02079 PMid:31157579
- Engstad CS, Gutteberg TJ, Osterud B. Modulation of blood cell activation by four commonly used anticoagulants. Thromb Haemost. 1997;77(4):690-6. PMid:9134644
- McFarland DC, Zhang C, Thomas HC, Ratliff TL. Confounding effects of platelets on flow cytometric analysis and cellsorting experiments using blood-derived cells. Cytometry A. 2006;69:86-94. https://doi.org/10.1002/cyto.a.20207 PMid:16419063
- Fesnak A, Lin C, Siegel DL, Maus MV. CAR-T cell therapies from the transfusion medicine perspective. Transfus Med Rev. 2016;30(3):139-45. https://doi.org/10.1016/j.tmrv.2016.03.001 PMid:27067907
- Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T. Chimeric antigen receptor (CAR) therapy for multiple myeloma. Br J Haematol. 2016;172(5):685-98. https://doi.org/10.1111/bjh.13889 PMid:26791002
- Wang Z, Chen C, Wang L, Jia Y, Qin Y. Chimeric antigen receptor T-cell therapy for multiple myeloma. Front Immunol. 2022;13:1050522. https://doi.org/10.3389/fimmu.2022.1050522 PMid:36618390
- Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo B, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;23(1):184-91. https://doi.org/10.1038/mt.2014.164 PMid:25174587
- Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128(13):1688-700. https://doi.org/10.1182/blood-2016-04-711903 PMid:27412889
- Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009;32(2):169-80. https://doi.org/10.1097/CJI.0b013e318194a6e8 PMid:19238016
- Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123-38. https://doi.org/10.1172/JCI85309 PMid:27111235
- El Marabti E, Abdel-Wahab O. Enhancing CD19 chimeric antigen receptor T cells through memory-enriched T cells. Clin Cancer Res. 2023;29(4):694-6. https://doi.org/10.1158/1078-0432.CCR-22-3232 PMid:36507801
- Arcangeli S, Bove C, Mezzanotte C, Camisa B, Falcone L, Manfredi F, et al. CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Invest. 2022;132(12):e150807. https://doi.org/10.1172/JCI150807 PMid:35503659
- Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cells. PLoS One. 2013;8(5):e64138. https://doi.org/10.1371/journal.pone.0064138 PMid:23741305
- Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227-42. https://doi.org/10.1038/nri3405 PMid:23470321
- Levine BL. Performance-enhancing drugs: Design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther. 2015;22(2):79-84. https://doi.org/10.1038/cgt.2015.5 PMid:25675873
- Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492-499. https://doi.org/10.1038/ni.2035 PMid:21739672
- Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290-7. https://doi.org/10.1038/nm.2446 PMid:21926977
- Barrett DM, Singh N, Liu X, Jiang S, June CH, Grupp SA, et al. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy. 2014;16(5):619-30. https://doi.org/10.1016/j.jcyt.2013.10.013 PMid:24439255
- Ghassemi S, Bedoya F, Nunez-Cruz S, June C, Melenhorst J, Milone M. Shortened T cell culture with IL-7 and IL-15 provides the most potent chimeric antigen receptor (CAR)-modified T cells for adoptive immunotherapy. Cancer Immunother Cancer Vaccines. 2016;24(Suppl 1):S79. https://doi.org/10.1016/S1525-0016(16)33012-X
- Ukrainskaya VM, Rubtsov YP, Pershin DS, Podoplelova NA, Terekhov SS, Yaroshevich I, et al. Antigen-specific stimulation and expansion of CAR-T cells using membrane vesicles as target cell surrogates. Small. 2021;17(45):2102643. https://doi.org/10.1002/smll.202102643 PMid:34605165
- Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, et al. Rapid manufacturing of non-activated potent CAR T cells. Nat Biomed Eng. 2022;6(2):118-28. https://doi.org/10.1038/s41551-021-00842-6 PMid:35190680
- Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. https://doi.org/10.1126/scitranslmed.3002842 PMid:21832238
- Casati A, Varghaei-Nahvi A, Feldman SA, Assenmacher M, Rosenberg SA, Dudley ME, et al. Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol Immunother. 2013;62(10):1563-73. https://doi.org/10.1007/s00262-013-1459-x PMid:23903715
- Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther. 2002;5(6):788-97. https://doi.org/10.1006/mthe.2002.0611 PMid:12027564
- Kebriaei P, Huls H, Singh H, Olivares S, Figliola M, Maiti S, et al. Adoptive therapy using sleeping beauty gene transfer system and artificial antigen presenting cells to manufacture T cells expressing CD19-specific chimeric antigen receptor. Blood. 2014;124:311. https://doi.org/10.1371/journal.pone.0064138
- Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study. Blood. 2013;122(17):2965-73. https://doi.org/10.1182/blood-2013-06-506741 PMid:24030379
- Lana MG, Strauss BE. Production of lentivirus for the establishment of CAR-T cells. Methods Mol Biol. 2020;2086:61-7. https://doi.org/10.1007/978-1-0716-0146-4_4 PMid:31707667
- Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817-28. https://doi.org/10.1182/blood-2011-04-348540 PMid:21849486
- Ghorashian S, Pule M, Amrolia P. CD19 chimeric antigen receptor T cell therapy for haematological malignancies. Br J Haematol. 2015;169(4):463-78. https://doi.org/10.1111/bjh.13340 PMid:25753571
- Hamada M, Nishio N, Okuno Y, Suzuki S, Kawashima N, Muramatsu H, et al. Integration mapping of piggyBac-Mediated CD19 chimeric antigen receptor T cells analyzed by novel tagmentation-assisted PCR. EBioMedicine. 2018;34:18-26. https://doi.org/10.1016/j.ebiom.2018.07.008 PMid:30082227
- Ramanayake S, Bilmon I, Bishop D, Dubosq MC, Blyth E, Clancy L, et al. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. Cytotherapy. 2015;17(9):1251-67. https://doi.org/10.1016/j.jcyt.2015.05.013 PMid:26212611
- Merten OW, Hebben M, Bovolenta C. Production of lentiviral vectors. Mol Ther Methods Clin Dev. 2016;3:16017. https://doi.org/10.1038/mtm.2016.17 PMid:27110581
- Sanber KS, Knight SB, Stephen SL, Bailey R, Escors D, Minshull J, et al. Construction of stable packaging cell lines for clinical lentiviral vector production. Sci Rep. 2015;5:9021. https://doi.org/10.1038/srep09021 PMid:25762005
- Wang X, Rivière I. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther. 2015;22(2):85-94. https://doi.org/10.1038/cgt.2014.81 PMid:25721207
- Ivics Z, Hackett PB, Plasterk RH, Izsvák Z. Molecular reconstruction of sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 1997;91(4):501-10. https://doi.org/10.1016/s0092-8674(00)80436-5 PMid:9390559
- Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF. The past, present, and future of non-viral CAR T cells. Front Immunol. 2022;13:867013. https://doi.org/10.3389/fimmu.2022.867013 PMid:35757746
- Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011;71(10):3516-27. https://doi.org/10.1158/0008-5472.CAN-10-3843 PMid:21558388
- Kebriaei P, Ciurea SO, Huls MH, Singh H, Olivares S, Su S, et al. Pre-emptive donor lymphocyte infusion with CD19-directed, CAR-modified T cells infused after allogeneic hematopoietic cell transplantation for patients with advanced CD19+ malignancies. Blood. 2015;126:862.
- Narayanavari SA, Chilkunda SS, Ivics Z, Izsvák Z. Sleeping Beauty transposition: From biology to applications. Crit Rev Biochem Mol Biol. 2017;52(1):18-44. https://doi.org/10.1080/10409238.2016.1237935 PMid:27696897
- Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017;5:22. https://doi.org/10.1186/s40364-017-0102-y PMid:28652918
- Gogol-Doring A, Ammar I, Gupta S, Bunse M, Miskey C, Chen W, et al. Genome-wide profiling reveals remarkable parallels between insertion site selection properties of the MLV retrovirus and the piggyBac transposon in primary human CD4(+) T cells. Mol Ther. 2016;24(3):592-606. https://doi.org/10.1038/mt.2016.11 PMid:26755332
- Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15(4):825-33. https://doi.org/10.1038/sj.mt.6300104 PMid:17299405
- Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transpl. 2010;16(9):1245-56. https://doi.org/10.1016/j.bbmt.2010.03.014 PMid:20304086
- Kaiser AD, Assenmacher M, Schroder B, Meyer M, Orentas R, Bethke U, et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther. 2015;22(2):72-8. https://doi.org/10.1038/cgt.2014.78 PMid:25613483
- Tumaini B, Lee DW, Lin T, Castiello L, Stroncek DF, Mackall C, et al. Simplified process for the production of anti-CD19-CAR-engineered T cells. Cytotherapy. 2013;15(11):1406-15. https://doi.org/10.1016/j.jcyt.2013.06.003 PMid:23992830
- Hanley PJ. Fresh versus frozen: Effects of cryopreservation on CAR T cells. Mol Ther. 2019;27(7):1213-4. https://doi.org/10.1016/j.ymthe.2019.06.001 PMid:31202635
- Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P, et al. Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics. Mol Ther. 2019;27(7):1275-85. https://doi.org/10.1016/j.ymthe.2019.05.015 PMid:31178392
- Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018;53:164-81. https://doi.org/10.1016/j.copbio.2018.01.025 PMid:29462761